SGLT2 Inhibitors and Heart Failure

This Harvard Medical School Continuing Education video examines the key question: what benefits can SGLT2 inhibitors provide to heart failure patients? Dr. Lee-Shing Chang, MD, an endocrinologist at Brigham and Women’s Hospital, reviews the cardiovascular outcomes trials that first indicated the benefit of SGLT2 inhibitors in heart failure patients as well as the current use of SGLT2 inhibitors in heart failure with both reduced and preserved injection fraction (HFrEF and HFpEF). Guidelines for patients with type 2 diabetes are discussed. 00:00 | Introduction 00:42 | Discovery of SGLT2 inhibitors for heart failure 02:50 | Key findings from HFrEF: DAPA-HF trial 04:05 | Key findings from HFrEF: EMPEROR-Reduced trial 04:51 | Key findings from HFpEF: EMPEROR-Preserved trial 06:22 | Discussion of trial applications and guidelines This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of Medicine, Massachusetts General Hospital; and Dr. Sugantha Sundar, MD, Assistant Professor of Anesthesia, Beth Israel Deaconess Medical Center, to validate the quality and accuracy of the content. It was edited by affiliate physicians of Harvard Medical School, Avanthi Raghavan, MD Cardiology Fellow, Massachusetts General Hospital. References: McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303  Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190  Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038  Notice: At this time, the content in this video is not accredited.